Skip to main content

Table 2 Comparison of PTV doses calculated from PVP, HAP and non-enhanced CTs

From: Hepatic arterial phase and portal venous phase computed tomography for dose calculation of stereotactic body radiation therapy plans in liver cancer: a dosimetric comparison study

  Dp Da Dn P(p,a,n)* (Dn-Dp)/Dn(%) P(p,n)# (Dn-Da)/Dn(%) P(a,n)# (Da-Dp)/Dn(%) P(p,a)#
3D-CRT           
CI 0.84 ± 0.07 0.83 ± 0.07 0.83 ± 0.07 0.116 -1.15 ± 2.44 - -0.49 ± 1.72 - -0.66 ± 1.00 -
HI 0.17 ± 0.02 0.17 ± 0.02 0.17 ± 0.02 0.117 1.04 ± 4.84 - -0.50 ± 5.77 - 1.54 ± 4.29 -
D98% (Gy) 46.83 ± 0.28 47.09 ± 0.41 47.36 ± 0.46 0.000 1.12 ± 0.78 0.000 0.56 ± 0.51 0.000 0.56 ± 0.58 0.000
D95% (Gy) 48.09 ± 0.06 48.36 ± 0.29 48.62 ± 0.40 0.000 1.10 ± 0.76 0.000 0.54 ± 0.58 0.000 0.56 ± 0.56 0.000
D50% (Gy) 53.17 ± 0.52 53.52 ± 0.57 53.83 ± 0.75 0.000 1.23 ± 0.81 0.000 0.58 ± 0.54 0.000 0.64 ± 0.56 0.000
D2% (Gy) 55.63 ± 1.14 56.09 ± 1.28 56.39 ± 1.43 0.000 1.33 ± 1.21 0.000 0.53 ± 1.09 0.000 0.81 ± 0.93 0.000
IMRT           
CI 0.85 ± 0.04 0.82 ± 0.06 0.79 ± 0.09 0.000 -8.60 ± 9.78 0.000 -4.34 ± 6.09 0.000 -4.25 ± 5.84 0.000
HI 0.05 ± 0.01 0.06 ± 0.01 0.06 ± 0.01 0.040 4.82 ± 8.30 0.006 2.58 ± 5.74 0.070 2.24 ± 5.70 0.111
D98% (Gy) 47.60 ± 0.20 47.85 ± 0.30 48.06 ± 0.45 0.000 0.94 ± 0.68 0.000 0.43 ± 0.49 0.000 0.51 ± 0.43 0.000
D95% (Gy) 48.05 ± 0.08 48.31 ± 0.23 48.54 ± 0.35 0.000 1.01 ± 0.72 0.000 0.46 ± 0.50 0.000 0.55 ± 0.51 0.000
D50% (Gy) 49.24 ± 0.30 49.54 ± 0.43 49.80 ± 0.48 0.000 1.11 ± 0.83 0.000 0.52 ± 0.62 0.000 0.59 ± 0.53 0.000
D2% (Gy) 50.28 ± 0.45 50.61 ± 0.51 50.91 ± 0.60 0.000 1.23 ± 0.99 0.000 0.59 ± 0.74 0.000 0.64 ± 0.66 0.000
VMAT           
CI 0.81 ± 0.08 0.79 ± 0.08 0.78 ± 0.10 0.000 -4.93 ± 6.74 0.000 -2.38 ± 4.89 0.002 -2.54 ± 2.91 0.000
HI 0.07 ± 0.02 0.08 ± 0.02 0.08 ± 0.02 0.137 1.92 ± 6.65 - -0.51 ± 4.73 - 2.43 ± 4.11 -
D98% (Gy) 47.45 ± 0.23 47.67 ± 0.32 47.89 ± 0.47 0.000 0.90 ± 0.64 0.000 0.45 ± 0.45 0.000 0.45 ± 0.38 0.000
D95% (Gy) 48.06 ± 0.04 48.28 ± 0.21 48.51 ± 0.31 0.000 0.93 ± 0.66 0.000 0.47 ± 0.42 0.000 0.46 ± 0.44 0.000
D50% (Gy) 49.98 ± 0.41 50.27 ± 0.51 50.52 ± 0.51 0.000 1.06 ± 0.79 0.000 0.49 ± 0.51 0.000 0.58 ± 0.52 0.000
D2% (Gy) 51.19 ± 0.62 51.54 ± 0.76 51.78 ± 0.80 0.000 1.13 ± 0.87 0.000 0.46 ± 0.53 0.000 0.68 ± 0.59 0.000
  1. Abbrevations: PVP, portal venous phase; HAP, hepatic arterial phase. Dp, Da and Dn were the dose calculated from portal venous phase, hepatic arterial phase and non-enhanced phase CTs respectively. 98%, 95%, 50% and 2%, were the minimum absorbed dose that covers 98%, 95%, 50% and 2% of the volume of the PTV respectively. CI, the conformity index; HI, the heterogeneity index. *, Friedman test; #, Wilcoxon signed ranks test.
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us